<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346330</url>
  </required_header>
  <id_info>
    <org_study_id>750P1C01</org_study_id>
    <nct_id>NCT03346330</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food-effect of TRK-750</brief_title>
  <official_title>An Exploratory, Randomised, Double-blind, Placebo-controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food-effect of TRK-750 in Healthy Adults and Patients With Peripheral Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Toray Industries, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Toray Industries, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, randomised, double-blind, placebo-controlled, Phase I study to assess
      the safety, tolerability, pharmacokinetics, pharmacodynamics and food-effect of single and
      multiple, ascending oral doses of TRK-750 in healthy adults and patients with peripheral
      neuropathic pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2017</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">August 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>Up to 10-14days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with clinically significant changes in laboratory safety tests</measure>
    <time_frame>Up to 10-14days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with morphological and/or rhythm abnormalities on electrocardiogram</measure>
    <time_frame>Up to 10-14days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with clinically significant changes in electrocardiogram time intervals</measure>
    <time_frame>Up to 10-14days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with clinically significant changes in vital signs:systolic blood pressure(mmHg)</measure>
    <time_frame>Up to 10-14days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with clinically significant changes in vital signs:diastolic blood pressure(mmHg)</measure>
    <time_frame>Up to 10-14days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with clinically significant changes in vital signs:pulse rate(bpm)</measure>
    <time_frame>Up to 10-14days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with clinically significant changes in vital signs:body temperature(Â°C)</measure>
    <time_frame>Up to 10-14days after last dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Healthy, Peripheral Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>TRK-750, single and multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, single and multiple doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRK-750</intervention_name>
    <description>TRK-750 capsule</description>
    <arm_group_label>TRK-750, single and multiple doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Placebo, single and multiple doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female volunteers

          -  Female subjects who are either:

               1. Non-childbearing potential, or permanently sterile OR

               2. Childbearing potential and agree to use at least one form of highly effective
                  contraception

          -  Male subjects, with a female sexual partner of childbearing potential or a pregnant or
             breastfeeding partner, must agree to use barrier contraception (male condom) for the
             treatment period and for at least three months after the end of the systemic exposure
             of the study drug.

          -  Satisfactory medical assessment with no clinically significant or relevant
             abnormalities.

          -  Ability to provide written, personally signed, and dated informed consent.

        Exclusion Criteria:

          -  Current or recurrent disease

          -  Current or relevant history of physical or psychiatric illness

          -  Positive test for Hepatitis B, Hepatitis C or human immunodeficiency virus antibody
             (HIV) at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>December 17, 2018</last_update_submitted>
  <last_update_submitted_qc>December 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic pain</keyword>
  <keyword>Neuropathic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

